Company / Capital Expenditures
VYNE Therapeutics Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$117.0K
FY2025
5-year range
$0 / $117.0K
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $117,000.
Based on SEC 10-K filings.
$117,000 in FY2025 with a 5-year CAGR of -27.1%.
Improved from $113,000 to $117,000 over the past 4 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -27.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.1%, indicating a declining trend.
- Peak capital expenditures was recorded in FY2020.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.0K | - |
| FY2024 | $0 | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $113.0K | -80.1% |
| FY2020 | $567.0K | +2000.0% |
| FY2019 | $27.0K | -12.9% |
| FY2018 | $31.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026